Allergan (NYSE:AGN) had its price target raised by UBS Group from $172.00 to $189.00 in a report published on Thursday, The Fly reports. They currently have a buy rating on the stock.

A number of other analysts also recently issued reports on AGN. Raymond James downgraded shares of Allergan from an outperform rating to a market perform rating in a report on Tuesday, June 25th. Mizuho downgraded shares of Allergan from a buy rating to a neutral rating and lifted their price target for the company from $171.00 to $188.00 in a report on Wednesday, June 26th. Goldman Sachs Group started coverage on shares of Allergan in a report on Tuesday, May 28th. They issued a neutral rating and a $154.00 price target on the stock. Cantor Fitzgerald lifted their price target on shares of Allergan from $125.00 to $165.00 and gave the company a neutral rating in a report on Wednesday, August 7th. Finally, Guggenheim downgraded shares of Allergan from a buy rating to a neutral rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have assigned a buy rating to the company’s stock. Allergan currently has an average rating of Hold and an average price target of $178.75.

NYSE AGN traded down $0.19 on Thursday, reaching $166.16. The company had a trading volume of 1,463,548 shares, compared to its average volume of 2,980,572. The company has a quick ratio of 0.91, a current ratio of 1.03 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $53.80 billion, a PE ratio of 9.96, a price-to-earnings-growth ratio of 1.69 and a beta of 1.61. The firm’s 50 day moving average price is $160.46 and its 200 day moving average price is $148.42. Allergan has a 12 month low of $114.27 and a 12 month high of $197.00.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.34 by $0.04. The company had revenue of $4.09 billion for the quarter, compared to the consensus estimate of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. Allergan’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.42 EPS. On average, research analysts expect that Allergan will post 16.69 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Tuesday, August 13th will be issued a $0.74 dividend. The ex-dividend date of this dividend is Monday, August 12th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.78%. Allergan’s dividend payout ratio (DPR) is presently 17.74%.

Several institutional investors have recently bought and sold shares of AGN. Clearbridge Investments LLC boosted its stake in shares of Allergan by 8.6% during the 1st quarter. Clearbridge Investments LLC now owns 9,167,006 shares of the company’s stock worth $1,342,141,000 after purchasing an additional 726,688 shares during the period. Longview Partners Guernsey LTD boosted its stake in shares of Allergan by 10.7% during the 2nd quarter. Longview Partners Guernsey LTD now owns 6,986,566 shares of the company’s stock worth $1,169,761,000 after purchasing an additional 676,771 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Allergan by 6.5% during the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock worth $990,867,000 after purchasing an additional 410,746 shares during the period. FMR LLC boosted its stake in shares of Allergan by 42.0% during the 1st quarter. FMR LLC now owns 6,042,005 shares of the company’s stock worth $884,611,000 after purchasing an additional 1,788,265 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Allergan by 6.6% during the 4th quarter. Geode Capital Management LLC now owns 4,000,839 shares of the company’s stock worth $533,767,000 after purchasing an additional 247,743 shares during the period. Hedge funds and other institutional investors own 80.86% of the company’s stock.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Read More: How to invest in a bear market

The Fly

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.